A group of independent vaccine advisers to the US Centers for Disease Control and Prevention is meeting this week, and a key item on the agenda is the hepatitis B vaccine. After presentations about ...
GlobalData forecasts the hepatitis B therapeutics market will more than double to $3.2B by 2034, driven by functional cure drugs despite pricing and generic challenges.
Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback